Additionally, a phase 3 international randomized trial, known as the PAPILLON study, further supports the efficacy of amivantamab in treating advanced non-small-cell lung cancer (NSCLC) with EGFR exon 20 insertions. Here, EGFR is linked to non-small cell lung carcinoma.